JournalArta
Tuesday, November 17, 2026 · JakartaS&P 7,326.92 ▼1.21%USD/IDR 18,233 ▼0.10%
JournalArta
Global Edition
beyond headlines
Advertisement

BCAL Diagnostics Expands Breast Cancer Research Beyond Lipids

BCAL Diagnostics has received ethics approval to study multiomic biomarkers in breast cancer screening, extending work previously focused on lipidomics. The company also reported one paper published in Scientific Reports and a second under revision after peer review, as it develops its blood-test research toward clinical applications.

By Elena Vance
November 17, 20262 min read
BCAL Diagnostics Expands Breast Cancer Research Beyond Lipids
BCAL Diagnostics Expands Breast Cancer Research Beyond Lipids

BCAL Diagnostics has received ethics approval to collect and analyze samples for multiomic assay development in breast cancer screening, extending research previously focused on lipids.

The Sydney company said a Human Research Ethics Committee approved an amendment to its existing breast cancer research program. BCAL widens breast cancer research to include epigenomic biomarkers, which it says may support future generations of its diagnostic assays.

The approval broadens the kinds of biomarkers the company can investigate. BCAL has not said that the expanded work has changed the clinical use of its existing test.

Advertisement

At the same time, BCAL has published a paper in Scientific Reports, a Nature Portfolio journal. It describes how the company developed breast cancer lipid biomarkers into a precise, quantitative laboratory assay.

BCAL said the paper sets out a clear, repeatable framework for moving research findings toward a test suitable for clinical use. The company also said it shows that the lipid signals underpinning its test can be measured reliably and reproducibly.

A second paper applies the lipid assay to patient samples from international cohorts. It uses machine learning to detect early-stage breast cancer from a blood sample.

The manuscript has been submitted to Communications Medicine, another Nature Portfolio journal, and is under revision following peer review. A preprint is available on medRxiv.

Advertisement

BCAL said the two papers together take its platform from a robust laboratory method through to clinical application. The second paper remains under review.

Chief Executive Anne-Louise Arnett said the expanded ethics approval would allow the company to examine additional types of biomarkers. “Our expanded ethics approval provides us with the ability to investigate complementary multiomic biomarkers in breast cancer. This has the potential to strengthen future generations of BREASTESTplus and broaden the diagnostic applications we can pursue from our scientific platform.”

Arnett also said peer-reviewed publications and conference presentations provide external validation of the company’s scientific and analytical framework. She described the work as relevant to translating BCAL’s lipidomics platform into diagnostic tests.

Advertisement

BCAL has presented research on BREASTESTplus 2, its test for early breast cancer detection. Dr. Mark David, the company’s Director of Mass Spectrometry and Clinical Scientist, presented a poster on the test’s clinical validation.

The poster was presented at the Australian Lipid Meeting 7 and the 5th International Lipidomics Society Conference, held in Perth from 18 to 21 October. A separate abstract on a blood-based lipidomic assay for loco-regional breast cancer recurrence has been accepted for the San Antonio Breast Cancer Symposium in December.

BCAL launched BREASTESTplus as a rule-out test for use in the clinical evaluation of breast disease in women with dense breasts. The company describes it as a non-invasive blood test used alongside mammography.

BCAL also holds an exclusive license from US precision diagnostics company ClearNote Health to sell and distribute the Avantect pancreatic, ovarian and multi-cancer blood tests in Australia and New Zealand.

Advertisement
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage
  2. 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI
  3. 3Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds
  4. 4NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur
  5. 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings
Advertisement
Don't Miss

Latest News

All stories →
  1. Indonesia · NewsKerch Bridge Loses Road Span in Ukrainian StrikeNov 17
  2. Technology · Apps & SoftwareApple Confirms iCloud, App Store and Apple Music Service IssuesNov 17
  3. Lifestyle · Food & Health13 Babies Born With Measles in U.S. Through September, Report SaysNov 17
  4. Lifestyle · Food & HealthOzempic and Mounjaro May Affect Memory, but Evidence Is MixedNov 17
  5. Advertisement
  6. World · EuropeUkraine Says Strikes Collapsed Kerch Bridge Road Span, Rail Line StandsNov 17
  7. World · AustraliaAlbanese and Trump Back New Quad Military ExercisesNov 17
  8. World · EuropeItaly Plans €42.5 Billion in Aerospace Spending Through 2039, Warns of Funding GapsNov 17
  9. World · AustraliaSo You Are Found in Sydney Skip Bin as Racing NSW ProbesNov 17